Page last updated: 2024-08-24

gemcitabine and pf 3758309

gemcitabine has been researched along with pf 3758309 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baldwin, G; He, H; Huynh, N; Nikfarjam, M; Wang, K; Wang, X	1

Other Studies

1 other study(ies) available for gemcitabine and pf 3758309

Article	Year
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine. International journal of oncology, 2018, Volume: 52, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Random Allocation	2018

Article

Year

Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.

International journal of oncology, 2018, Volume: 52, Issue:1

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Random Allocation

2018